top of page
Pharmaco%2520(MC)%252049_edited_edited.jpg

Recherche / Research

List of publications

For the complete list of publications, please refer to Google Scholar by clicking on the link below

1. Reaction Cascades

There is an undeniable interest from organic chemists and from the pharmaceutical industry to access complex alkaloids in short order. It is well established that one-pot reaction cascades or sequences are an excellent avenue to increase molecular complexity in a single operation. However, there are enormous challenges associated with this strategy: because all required functional groups must be present on the substrate for the key transformation, we have to address issues of chemoselectivity, diastereoselectivity, and regioselectivity. Over the past years, we generated the skeletons of a wide span of alkaloids of biological interest by successfully developing several reaction cascades such as those detailed below.

Sequence of Vislmeier-Haack Cyclization and Intramolecular Azomethine Ylide Cycloaddition

Daphnyphyllum Alkaloids

This one-step cyclization sequence is the most impressive we have developed. On highly functionalized linear substrates, we can activate the amide with perfect chemoselectivity and then generate a first cycle by nucleophilic trapping. Subsequent generation of an azomethine ylide in situ finally allows intramolecular cycloaddition. We then applied this approach to the construction of the tetracyclic backbone of two of the 14 Daphnyphyllum alkaloid subfamilies known for more than 35 years but for which no synthesis has been completed to date. Our approach allowed the construction of the most advanced compound published so far in these 2 subfamilies, by generating 3 cycles and 5 stereogenic centers in one operation. effectiveness of a cascading cyclization approach.These applications clearly establish the efficiency and high potential of this new reaction cascade, which will tremendously facilitate the construction of polycyclic natural products.

​

Lévesque, F.; Bélanger,* G. «A Versatile Cascade of Intramolecular Vilsmeier-Haack – Azomethine Ylide Generation – 1,3-Dipolar Cycloaddition Toward Tricyclic Cores of Alkaloids» Org. Lett. 2008, 10, 4939-4942

Bélanger,* G.; Boudreault, J.; Lévesque, F. «Synthesis of the Tetracyclic Core of Daphnilactone B-Type and Yuzurimine-Type Alkaloids» Org. Lett. 2011, 13, 6204-6207

Boudreault, J.; Lévesque, F.; Bélanger,* G. «Studies toward Total Synthesis of (+/-)-Caldaphnidine C via One-Pot Sequential Intramolecular Vilsmeier-Haack and Azomethine Ylide 1,3-Dipolar Cycloaddition» J. Org. Chem. 2016, 81, 9247-9268

​

​

daph.gif

Calyciphylline B - Type Alkaloids

A suitably functionalized tricyclic adduct containing the common A,B,E rings found in calyciphylline B–type alkaloids was obtained in 9 linear steps. The key transformation features an efficient one-pot sequence of intramolecular Vilsmeier-Haack cyclization and azomethine ylide 1,3-dipolar cycloaddition in which three cycles, three new carbon-carbon bonds and three stereocenters are formed, one being fully substituted. This work also demonstrates the first use of a chiral, non racemic cyclic enol ether as an internal carbon nucleophile.

​

Boissarie, P.; Bélanger,* G. «Short Approach toward the Nonracemic A,B,E Tricyclic Core of Calyciphylline B-Type Alkaloids» Org. Lett. 2017, 14, 3739-3742

Calyciphylline B.gif

Aspidospermatan Alkaloids

The development of a new one-pot reaction sequence afforded the tricyclic core of several aspidospermatan-type alkaloids from a linear, densely functionalized substrate. The key sequence features a highly chemoselective formamide activation that triggered a Vilsmeier-Haack cyclization, followed by an azomethine ylide generation and intramolecular cycloaddition. The choice of nucleophile, azomethine ylide precursor and dipolarophile was crucial to the success of the sequence.

​

Hauduc, C.; Bélanger,* G. «General Approach toward Aspidospermatan-Type Alkaloids Using One-Pot Vilsmeier-Haack Cyclization and Azomethine Ylide Cycloaddition» J.  Org. Chem. 2017, 82, 4703-4712

Aspidospermatan.gif

Cascade of Vilsmeier-Haack and (Organocatalyzed) Mannich Cyclizations

Indolizidines and quinolizidines

Substituted indolizidines and quinolizidines are attractive molecular scaffold because of their high occurrence in natural products exhibiting notable biological activity, as represented by the Erythrina family (erythraline shown), (+)-oleracein E, (+)-harmicine, (–)-tangutorine, and vincamine. These scaffolds could also be found in several drugs developed by the pharmaceutical industry.

quinolizidines.gif

Vilsmeier-Haack and Mannich Cyclization Cascade

vhm2.gif

Total Synthesis of Virosine A

The development of a new one-pot sequential cyclizations involving a Vilsmeier-Haack reaction followed by an organocatalyzed Mannich reaction proved to be a valuable synthetic strategy to give access to functionalized indolizidines and quinolizidines in one operation from readily synthesized precursors.

​

Org. Lett. 2008, 10, 4501-4504

J. Org. Chem. 2012, 77, 3215-3221

virA.gif

Vilsmeier-Haack and Organocatalyzed Mannich Cyclization Cascade

The methodology was further expanded to an organocatalyzed  version of the Mannich reaction as the second cyclization step. This improved the span of nucleophiles that could be used and proved to be a valuable synthetic strategy to give access to functionalized indolizidines and quinolizidines in one operation from readily synthesized precursors.

​

J. Org. Chem. 2020, 85, 4712-4729

V-H organocat Mannich.gif

Synthesis of Highly Substituted β-Amino Acids

b-aminoacids.gif

A good proportion of candidate molecules for drug development or as molecular probes for imaging are peptide-based, which causes significant problems often due to low stability against enzymatic degradation. For decades, chemists have worked to develop solutions to this problem by substituting natural amino acids by amide isosteres (e.g. fluoroalkene), non-natural α-amino acids, and β-amino acids. The latter offer a significant advantage over the first two: by the addition of a carbon atom between the acid and the amine function, it is possible to increase the degree of substitution (and targeted functionalization) on β-amino acids to a level that could not be reached with amide isosteres or β-amino acids. Another benefit often overlooked is the ability to predict and induce local secondary structure (β-sheet, alpha-helix) based on the substitution pattern of β-amino acids. Access to highly substituted β-amino acids is therefore of crucial importance for all applications involving peptides as molecular recognition units. However, the production of these molecules is still quite challenging nowadays. We recently published a novel, convergent, and versatile access to β2,2- and β2,2,3-amino acids, bearing a quaternary center adjacent to a secondary or tertiary center, respectively, based on our amide activation method and Vilsmeier-Haack trapping with ketene silyl acetals. Such highly substituted β-amino acid derivatives are essentially not accessible using previously reported methods.

​

Org. Lett. 2015, 17, 322-325

2. Medicinal Chemistry

Design and Synthesis of New Agonists of the Keap1/Nrf2/ARE Pathway

Keap1.jpg

The Keap1/Nrf2/ARE pathway controls a series of genes coding for cytoprotective proteins against oxidative and electrophilic stress (OES), as well as inflammation. Scientific research has linked OES to over 200 diseases and conditions such as cancers or neurodegenerative disorders. Keap1 is a protein recognized as a therapeutic target to regulate the response to OES with high potential. Keap1 has two main binding sites; although most actors in this field targets a well-characterized site, we rather decided to study a much less known binding site (IVR) that contains at least 4 cystein residues. Since this part of Keap1 is not well defined, this project has two goals: to better understand and to take advantage of this second binding site for the development of novel Keap1-Nrf2 interaction inhibitors. We hypothesized that the cysteine-rich active site of Keap1 could be targeted with molecules containing two Nazarov acceptors. A series of 33 compounds was designed, synthesized and biologically evaluated. To our delight, our results so far confirm our hypothesis.

​

J. Med. Chem. 2016, 59, 9431-9442

bottom of page